Literature DB >> 18679050

Gamma-aminobutyric acid inhibits synergistic interleukin-6 release but not transcriptional activation in astrocytoma cells.

Joseph D Roach1, Grant T Aguinaldo, Kaumudi Jonnalagadda, Francis M Hughes, Bryan L Spangelo.   

Abstract

OBJECTIVE: A decline in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) may enhance cytokine release in Alzheimer's disease (AD) resulting in neuroinflammation. We investigated the GABA-mediated suppression of the synergistic release of interleukin (IL)-6 due to interleukin 1-beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha).
METHODS: Rat C6 astrocytoma cells were treated with IL-1 beta and TNF-alpha in the absence and presence of GABA. Activation of p38, degradation of I kappaB-alpha and total cellular IL-6 were determined by Western blot analysis. IL-6 release and gene expression were measured by ELISA and RT-PCR, respectively.
RESULTS: Although p38 and nuclear factor (NF)-kappaB are essential for the synergistic release of IL-6, GABA did not affect either p38 phosphorylation or I kappaB-alpha degradation. Additionally, GABA suppressed IL-6 release but did not alter cytokine-driven synergistic increases in IL-6 gene expression. Western blot analysis revealed that co-treatments with IL-1 beta and TNF-alpha resulted in an increase in intracellular IL-6 that was prevented by GABA.
CONCLUSION: GABA-induced inhibition of IL-6 release appears to coincide with a reduction in cellular IL-6. The GABA-induced suppression of IL-6 release may include inhibition of IL-6 gene translation. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18679050      PMCID: PMC2859952          DOI: 10.1159/000148194

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  30 in total

1.  Development of GABA(A) receptor-mediated inhibitory postsynaptic currents in hippocampus.

Authors:  Matthew I Banks; Jason B Hardie; Robert A Pearce
Journal:  J Neurophysiol       Date:  2002-12       Impact factor: 2.714

Review 2.  Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention.

Authors:  Martin Braddock; Anthony Quinn
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

3.  Identified sources and targets of slow inhibition in the neocortex.

Authors:  Gábor Tamás; Andrea Lorincz; Andrea Simon; János Szabadics
Journal:  Science       Date:  2003-03-21       Impact factor: 47.728

4.  Loss of Ikappa B-beta is associated with prolonged NF-kappa B activity in human glial cells.

Authors:  E Bourke; E J Kennedy; P N Moynagh
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

5.  Effect of GABA on GnRH neurons switches from depolarization to hyperpolarization at puberty in the female mouse.

Authors:  Seong-Kyu Han; Istvan M Abraham; Allan E Herbison
Journal:  Endocrinology       Date:  2002-04       Impact factor: 4.736

6.  Murine gamma-herpesvirus-68-induced IL-12 contributes to the control of latent viral burden, but also contributes to viral-mediated leukocytosis.

Authors:  Sherine F Elsawa; Kenneth L Bost
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

7.  GABAB receptor modulation of rapid inhibitory and excitatory neurotransmission from subfornical organ and other afferents to median preoptic nucleus neurons.

Authors:  Miloslav Kolaj; Donglin Bai; Leo P Renaud
Journal:  J Neurophysiol       Date:  2004-02-18       Impact factor: 2.714

8.  Somatostatin and gamma-aminobutyric acid inhibit interleukin-1 beta-stimulated release of interleukin-6 from rat C6 glioma cells.

Authors:  Bryan L Spangelo; Scott Horrell; Amy L Goodwin; Sachin Shroff; W David Jarvis
Journal:  Neuroimmunomodulation       Date:  2004       Impact factor: 2.492

9.  Thiopental inhibits tumor necrosis factor alpha-induced activation of nuclear factor kappaB through suppression of kappaB kinase activity.

Authors:  Torsten Loop; Matjaz Humar; Soeren Pischke; Alexander Hoetzel; Rene Schmidt; Heike L Pahl; Klaus K Geiger; Benedikt H J Pannen
Journal:  Anesthesiology       Date:  2003-08       Impact factor: 7.892

Review 10.  The interleukin-1 system: an attractive and viable therapeutic target in neurodegenerative disease.

Authors:  S M Allan; E Pinteaux
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2003-10
View more
  4 in total

1.  Transgene-mediated GDNF expression enhances synaptic connectivity and GABA transmission to improve functional outcome after spinal cord contusion.

Authors:  Angela Koelsch; Yongjia Feng; David J Fink; Marina Mata
Journal:  J Neurochem       Date:  2010-02-02       Impact factor: 5.372

Review 2.  Neuroendocrine immunoregulation in multiple sclerosis.

Authors:  Nathalie Deckx; Wai-Ping Lee; Zwi N Berneman; Nathalie Cools
Journal:  Clin Dev Immunol       Date:  2013-12-08

3.  Overexpression of BDNF increases excitability of the lumbar spinal network and leads to robust early locomotor recovery in completely spinalized rats.

Authors:  Ewelina Ziemlińska; Sebastian Kügler; Melitta Schachner; Iwona Wewiór; Julita Czarkowska-Bauch; Małgorzata Skup
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

4.  Discovery of Anti-inflammatory Ingredients in Chinese Herbal Formula Kouyanqing Granule based on Relevance Analysis between Chemical Characters and Biological Effects.

Authors:  Hong Liu; Yan-fang Zheng; Chu-yuan Li; Yu-ying Zheng; De-qin Wang; Zhong Wu; Lin Huang; Yong-gang Wang; Pei-bo Li; Wei Peng; Wei-wei Su
Journal:  Sci Rep       Date:  2015-12-10       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.